Analysis of adriamycin and adriamycinol in micro volumes of rat plasma

Bots, A.M.B.; Oort, W. J. van; Noordhoek, J.; Dijk, Anouk van; Klein, S. W.; Hoesel, Q.G.C.M. van

doi:10.1016/s0378-4347(00)86151-4

Cited by 35 publications

(17 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…. At different times after drug administration, animals were killed; organs were rapidly removed and tissue concentrations of DOXO were measured according to Bots et al [35], with modifications [16]. Each entry is the mean value from determinations in three animals.…”

Section: Effect Of Free and Coupled Doxo On Body Weight And On Tumor mentioning

confidence: 99%

“…One week after the last day of DENA administration, they were injected in the dorsal vein of penis under isoflurane anesthesia with free or coupled DOXO and were killed at the indicated times after drug injection. Organs were rapidly removed and tissue concentrations of DOXO were measured according to Bots et al [35], with modifications [16]. Fig.…”

Section: Histology and Histochemistrymentioning

confidence: 99%

See 1 more Smart Citation

Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine

Fiume

Bolondi

Busi

et al. 2005

Journal of Hepatology

View full text Add to dashboard Cite

Section: Effect Of Free and Coupled Doxo On Body Weight And On Tumor mentioning

confidence: 99%

Section: Histology and Histochemistrymentioning

confidence: 99%

Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine

Fiume

Bolondi

Busi

et al. 2005

Journal of Hepatology

View full text Add to dashboard Cite

“…[27] Doxorubicin and its metabolite doxorubicinol (DXOH) were extracted following the description given in Ref. [28] . Briefly, 100 mL plasma or tissue sample was pipetted in an Ependorff test tube, to which 100 mL borate buffer (pH ¼ 9), 500 mL chloroform : heptanol (1 : 1, v/v) and 10 mL daunorubicin (DNR) (50 mg/mL) (used as internal standard to correct for losses due to extraction procedure), were added.…”

Section: Biodistribution Studymentioning

confidence: 99%

Biodistribution Study of Doxorubicin Encapsulated in Liposomes: Influence of Peptide Coating and Lipid Composition

Almiñana

Polo

Rodríguez

et al. 2004

Preparative Biochemistry and Biotechnology

View full text Add to dashboard Cite

In this paper we describe the biodistribution of doxorubicin (DXR) encapsulated in three different types of liposomes. Common composition was hydrogenated phosphatidylcholine (HPC)/phosphatidylglycerol (PG) cholesterol (Chol)/X, X being either 10% N-glutaryl phosphatidylethanolamine (NGPE), 10% NGPE + 6% distearoyl-phosphatidylethanolamine-polyethyleneglycol 2000 (DSPE-PEG), or 10% NGPE + 6% DSPE-PEG-COOH. These series of vesicles were coated with an active or an inactive sequence of laminin (laminin receptors, integrins, are overexpressed in tumor cells). Single doses of these preparations were injected, i.v., into healthy mice. For biodistribution experiments, mice were sacrificed at three different time-points post-treatment. Doxorubicin and doxorubicinol (DXOH) levels were determined in plasma, heart, lung, kidney, spleen, and liver using HPLC with daunorubicin (DNR) as internal standard. The results obtained indicate that compositions containing DSPE-PEG have the longest half-lives in plasma, as was to be expected according to the data in the literature. However, the presence of the peptides on the surface of liposomes reduces concentration values in this tissue. Distribution in other organs reveals high differences, among the liposomal samples studied, depending mainly on the presence of active or inactive peptide on the surface of vesicles. Liposomes coated with the laminin active sequence show lower accumulation in studied tissues than free DXR. This indicates that heart toxicity, associated to DXR treatments, could be diminished, and open promising perspectives for its future study in tumor-bearing animals.

show abstract

“…These two preventive measures were carried out to minimize DXR adsorption to glassware and HPLC system. The identification of DXR and its degradation derivatives was performed using the HPLC method of Bots et al (39) with minor modifications. The HPLC systems used were those described above.…”

Section: Assaysmentioning

confidence: 99%

Preparation and Characterization of Liposomal Doxorubicin for Human Use

Amselem¹,

Cohen²,

Druckmann³

et al. 1992

Journal of Liposome Research

View full text Add to dashboard Cite

A liposome-associated doxorubicin formulation that has been utilized in two phase Iclinical trials at two separate medical centers is described. This work deals with formulation optimization, process development, quality control assays on raw materials, characterization assays for these liposomes, and their short-term stability. One of the main goals of this work is to provide a model for the production of liposomal formulations of sufficient quantity and quality to be used in clinical trials.Vials containing 50 mg doxorubicin HCI and 250 mg lactose were obtained from Farmitalia -Car10 Erba (Milan, Italy). Des feralDeferoxamine mesylate, an iron chelating agent, was from Ciba Geigy (Basel, Switzerland). Do wexDowex 5OWX-4, analytical grade, 200-400 mesh, cation exchange resin was obtained from Dow Chemical Company (supplied by Aldrich Chemical Co.

show abstract

Analysis of adriamycin and adriamycinol in micro volumes of rat plasma

Cited by 35 publications

References 12 publications

Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine

Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine

Biodistribution Study of Doxorubicin Encapsulated in Liposomes: Influence of Peptide Coating and Lipid Composition

Preparation and Characterization of Liposomal Doxorubicin for Human Use

Contact Info

Product

Resources

About